论文部分内容阅读
转移性肾癌(mRCC)对放疗、化疗均不敏感,虽然靶向治疗为转移性肾癌的治疗提供了新的治疗方案,但免疫疗法一直作为治疗转移性肾癌的基础疗法。在过去的20年中,研究者也一直在研究新的免疫疗法,研究方向趋向于研究各种细胞因子,其中最主要的有IFN-α和IL-2两种,二者可以明显提高患者的生存时间。但是转移性肾癌的细胞因子疗法仍需进一步优化,本文总结了使用细胞因子治疗转移性肾癌的Ⅲ期临床试验,以期为转移性肾癌细胞因子疗法的合理选择提供参考。
Metastatic renal cell carcinoma (mRCC) is not sensitive to radiotherapy and chemotherapy. Although targeted therapy has provided a new treatment for the treatment of metastatic renal cell carcinoma, immunotherapy has been the basic therapy for metastatic renal cell carcinoma. In the past 20 years, researchers have been studying new immunotherapy. The research direction tends to study various cytokines. The most important ones are IFN-α and IL-2, both of which can significantly improve the patients’ Survival time. However, the cytokine therapy of metastatic renal cell carcinoma needs to be further optimized. This paper summarizes the phase Ⅲ clinical trial of cytokine treatment of metastatic renal cell carcinoma in order to provide a reference for the rational choice of cytokine therapy for metastatic renal cell carcinoma.